• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

AVA, Braun Launches Solution to Simplify IV Delivery for Patients

by Jasmine Pennic 04/30/2021 Leave a Comment

AVA, Braun Launches Solution to Simplify IV Delivery for Patients

What You Should Know:

–  B. Braun Medical Inc. (B. Braun), a provider of infusion therapy and pain management, unveiled Peripheral Advantage, a new program that is designed to improve patients’ experience with peripheral intravenous (IV) therapy. 

– The comprehensive program combines clinical instruction, data-driven insights and advanced tools to empower nurses to achieve first-stick success and help prevent many of the complications associated with peripheral IV therapy.

– Peripheral Advantage, which is now available to all hospitals nationwide, addresses a long tolerated, yet unacceptable reality: Although vascular access is the most common invasive procedure, most nurses are not provided with the training, techniques or tools they need to achieve first-stick success. 


Why It Matters

Only 57% or less of nursing students receive any form of Peripheral Intravenous Catheter (PIVC) training.1 As a result, many patients endure multiple needle sticks or repeated IV insertions during treatment.

Research shows that PIVC restarts subject patients to discomfort, and most importantly introduce greater risk of infection and other complications, while also generating additional costs.2 With up to 69% of peripheral IV lines failing before treatment is completed,3 Peripheral Advantage is designed to decrease the number of PIVCs required to complete therapy.

Peripheral Advantage is designed to optimize clinical skills and product performance for better clinical outcomes. Real-word data is collected throughout the program to provide baseline and ongoing insights and analytics to healthcare leadership to help gauge the program’s impact on areas including patient satisfaction, first stick success, IV catheter dwell time, and overall cost containment.

Additional components include:

– Professional on-site clinical instruction: B. Braun’s PIVC clinical experts provide nurses with an established curriculum of extensive training on the best techniques for peripheral IV insertions, maintenance and care to help improve their first stick placement, increase dwell time and decrease complications. Peripheral Advantage also includes an accredited online course for which participants can receive continuing education credits.

– A complete set of cutting-edge tools: Training is also provided in the use of B. Braun’s advanced tools and products. This includes the company’s STEADYCARETM Extension Set Technology, which helps stabilize the catheter and maintain the insertion angle, as well as the Introcan Safety® Family of IV Catheters and VeinViewer® Vein Visualization Technology, a device distributed by B. Braun that uses near-infrared light to provide clinicians with an accurate view of patients’ veins. Collectively, the tools and the education seek to reduce the number of PIVC insertion attempts a patient receives during a given therapy, thus helping to improve patient experience.

“There is a clear need in the healthcare system to improve instruction on the placement and maintenance of IV catheters,” said Judy Thompson, MSNEd, RN, VA-BC™, Director of Clinical Education, Association for Vascular Access. “We have been pleased to collaborate with B. Braun on the development of new educational resources for nursing and other healthcare schools. Expanding the use of these training resources to health systems will go a long way to raise the standard of care and improve the experience of caregivers and patients alike.”

References

1. Glover KR, Stahl BR, Murray C, et al. A Simulation-Based Blended Curriculum for Short Peripheral Intravenous Catheter Insertion: An Industry-Practice Collaboration. J Contin Educ Nurs. Sep 1 2017;48(9):397-406.doi:10.3928/00220124-20170816-0

2. Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015 May-Jun;38(3):189-203. doi: 10.1097/NAN.0000000000000100

3. Cooke M. et al. Not “just” an IV line: consumer perspectives on PIVC. PLoS ONE. 2018;13(2).

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |